Vanguard Personalized Indexing Management LLC Boosts Stock Position in Metagenomi, Inc. $MGX

Vanguard Personalized Indexing Management LLC grew its holdings in shares of Metagenomi, Inc. (NASDAQ:MGX) by 53.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,515 shares of the company’s stock after purchasing an additional 7,458 shares during the period. Vanguard Personalized Indexing Management LLC owned about 0.06% of Metagenomi worth $32,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of MGX. AQR Capital Management LLC purchased a new stake in Metagenomi during the 1st quarter worth about $119,000. Nuveen LLC acquired a new position in shares of Metagenomi during the first quarter worth about $86,000. Bank of New York Mellon Corp grew its position in shares of Metagenomi by 39.6% during the first quarter. Bank of New York Mellon Corp now owns 50,387 shares of the company’s stock worth $69,000 after buying an additional 14,296 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Metagenomi during the first quarter worth about $43,000. Finally, Bank of America Corp DE grew its holdings in Metagenomi by 482.9% during the 4th quarter. Bank of America Corp DE now owns 21,113 shares of the company’s stock worth $76,000 after acquiring an additional 17,491 shares in the last quarter.

Analyst Ratings Changes

MGX has been the subject of several analyst reports. Wall Street Zen raised Metagenomi from a “sell” rating to a “hold” rating in a research report on Saturday. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Metagenomi in a report on Tuesday, August 19th. Wells Fargo & Company lowered their price target on Metagenomi from $16.00 to $12.00 and set an “overweight” rating for the company in a report on Thursday, August 14th. Zacks Research upgraded shares of Metagenomi from a “hold” rating to a “strong-buy” rating in a report on Friday, October 17th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Metagenomi in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Metagenomi Stock Down 5.2%

NASDAQ:MGX opened at $2.74 on Tuesday. The company has a market capitalization of $102.83 million, a PE ratio of -1.16 and a beta of 0.27. Metagenomi, Inc. has a 52-week low of $1.23 and a 52-week high of $4.92. The stock has a fifty day simple moving average of $2.32 and a 200-day simple moving average of $1.96.

Metagenomi (NASDAQ:MGX) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.14. The firm had revenue of $8.51 million during the quarter, compared to the consensus estimate of $7.72 million. Metagenomi had a negative return on equity of 37.84% and a negative net margin of 257.99%. As a group, equities analysts anticipate that Metagenomi, Inc. will post -2.46 earnings per share for the current year.

About Metagenomi

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.